Ana Vujaklija Brajkovic, Andrej Markota, Luka Bielen, Andro Vujević, Mia Rora, Radovan Radonic
{"title":"血管紧张素II在严重血小板减少症和慢性静脉血栓中的应用：1例报告。","authors":"Ana Vujaklija Brajkovic, Andrej Markota, Luka Bielen, Andro Vujević, Mia Rora, Radovan Radonic","doi":"10.5492/wjccm.v13.i4.96755","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The initial trials on angiotensin II (AT II) administration indicated a high incidence of thrombocytopenia and thrombosis, as well as a positive correlation between hyperreninemia and response to the medication.</p><p><strong>Case summary: </strong>We describe a case of a patient presenting with catecholamine resistant septic shock, thrombocytopenia, deep vein thrombosis, and normal renin concentration who responded immediately to AT II treatment. We observed no worsening of thrombocytopenia and no progression of thrombosis or additional thromboses during treatment.</p><p><strong>Conclusion: </strong>Our case underscores the need for individualized assessment of patients for potential therapy with AT II.</p>","PeriodicalId":66959,"journal":{"name":"世界危重病急救学杂志(英文版)","volume":"13 4","pages":"96755"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577538/pdf/","citationCount":"0","resultStr":"{\"title\":\"Angiotensin II administration in severe thrombocytopenia and chronic venous thrombosis: A case report.\",\"authors\":\"Ana Vujaklija Brajkovic, Andrej Markota, Luka Bielen, Andro Vujević, Mia Rora, Radovan Radonic\",\"doi\":\"10.5492/wjccm.v13.i4.96755\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The initial trials on angiotensin II (AT II) administration indicated a high incidence of thrombocytopenia and thrombosis, as well as a positive correlation between hyperreninemia and response to the medication.</p><p><strong>Case summary: </strong>We describe a case of a patient presenting with catecholamine resistant septic shock, thrombocytopenia, deep vein thrombosis, and normal renin concentration who responded immediately to AT II treatment. We observed no worsening of thrombocytopenia and no progression of thrombosis or additional thromboses during treatment.</p><p><strong>Conclusion: </strong>Our case underscores the need for individualized assessment of patients for potential therapy with AT II.</p>\",\"PeriodicalId\":66959,\"journal\":{\"name\":\"世界危重病急救学杂志(英文版)\",\"volume\":\"13 4\",\"pages\":\"96755\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577538/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"世界危重病急救学杂志(英文版)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5492/wjccm.v13.i4.96755\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"世界危重病急救学杂志(英文版)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5492/wjccm.v13.i4.96755","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Angiotensin II administration in severe thrombocytopenia and chronic venous thrombosis: A case report.
Background: The initial trials on angiotensin II (AT II) administration indicated a high incidence of thrombocytopenia and thrombosis, as well as a positive correlation between hyperreninemia and response to the medication.
Case summary: We describe a case of a patient presenting with catecholamine resistant septic shock, thrombocytopenia, deep vein thrombosis, and normal renin concentration who responded immediately to AT II treatment. We observed no worsening of thrombocytopenia and no progression of thrombosis or additional thromboses during treatment.
Conclusion: Our case underscores the need for individualized assessment of patients for potential therapy with AT II.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
